Long Term Nebulised Gentamicin in Patients With Bronchiectasis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00749866
Recruitment Status : Completed
First Posted : September 9, 2008
Last Update Posted : August 10, 2010
NHS Lothian
Information provided by:
University of Edinburgh

September 8, 2008
September 9, 2008
August 10, 2010
May 2007
August 2009   (Final data collection date for primary outcome measure)
Reduction in bacterial load [ Time Frame: 1 year ]
Same as current
Complete list of historical versions of study NCT00749866 on Archive Site
  • airways and systemic inflammation [ Time Frame: 1 year ]
  • Spirometry and exercise capacity [ Time Frame: 1 year ]
  • Exacerbation frequency [ Time Frame: 1 year ]
  • Health Related Quality of Life [ Time Frame: 1 Year ]
  • Long term safety with nebulised Gentamicin [ Time Frame: 1 Year ]
Same as current
Not Provided
Not Provided
Long Term Nebulised Gentamicin in Patients With Bronchiectasis
Can Long Term Nebulised Gentamicin Reduce The Bacterial Burden, Break the Vicious Cycle of Inflammation and Improve Quality of Life in Patients With Bronchiectasis
The hypothesis of this randomized placebo controlled trial is that targeted nebulized gentamicin to the airways will reduce bacterial burden and limit neutrophil airways inflammation. If given long term this will improve symptoms, pulmonary physiology, exercise capacity and health related quality of life with a reduction in exacerbation frequency and health care utilization.
Not Provided
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
  • Drug: Gentamicin
    Nebulised 80mg twice daily
  • Drug: Saline
    Nebulised 4mls 0.9% Saline twice daily
  • Active Comparator: 1
    Nebulised Gentamicin
    Intervention: Drug: Gentamicin
  • Placebo Comparator: 2
    Nebulised 0.9% Saline
    Intervention: Drug: Saline

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
August 2009
August 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Bronchiectasis confirmed by HRCT of the chest
  • Clinically stable (not requiring antibiotics for at least 4 weeks preceding the study start date)
  • Aged 18-70
  • Chronic sputum production > 5 mls for the majority of days in 3 months before enrolment
  • Chronically colonized (on at least 2 occasions in the preceding 12 months) whilst clinically stable
  • At least two exacerbations in the past year
  • Patients able to tolerate a nebulized gentamicin challenge
  • FEV1 > 30% predicted
  • Smoking < 20 pack year history and ex-smokers >1 year.

Exclusion Criteria:

  • Cystic fibrosis
  • Emphysema on HRCT chest
  • Thoracic surgery within the past 1 year
  • Allergic bronchopulmonary aspergillosis
  • Poorly controlled asthma ( > 20% diurnal variation in peak expiratory flows despite treatment)
  • Unstable angina or uncontrolled congestive cardiac failure
  • Active malignancy
  • Pregnancy or breast feeding
  • Creatinine clearance < 30 mls/minute
  • Vestibular instability
  • Previous documented intolerance to aminoglycosides
Sexes Eligible for Study: All
18 Years to 70 Years   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
United Kingdom
Not Provided
Not Provided
Dr Adam Hill; Consultant Physician and Honorary Senior Lecturer, NHS Lothian and University of Edinburgh
University of Edinburgh
NHS Lothian
Principal Investigator: Adam T Hill, MBChB MD NHS Lothian and University of Edinburgh
University of Edinburgh
August 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP